You are currently viewing a placeholder content from YouTube. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
Speakers
Dr. Dominik Schumacher
CEO Tubulis
Topic: Our path to pharma partnership: positioning Tubulis in the highly competitive ADC market
Tubulis entered into a strategic partnership with Bristol Myers Squibb in April 2023 to develop next-generation ADCs in oncology. The deal includes an upfront payment of $22.75 million to Tubulis and milestone payments of more than $1 billion.
Prof. Julian Grünewald
TUM
Topic: CRISPR therapies for a new era of genomic medicine
The first approval of a CRISPR therapy is expected in 2023. A large number of new gene editing technologies were developed in recent years. Many of these are mechanistically different from the classic “genetic scissors”. This talk will be about the current state of CRISPR technology development and clinical translation.
.
Welcome / Moderation
Dr. Peter Hanns Zobel
Managing Director of the IZB
Topic:
News from the IZB
